Parkwood LLC lessened its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) by 14.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,553 shares of the biotechnology company’s stock after selling 2,876 shares during the quarter. Parkwood LLC’s holdings in Ascendis Pharma A/S were worth $2,144,000 at the end of […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) had its price target increased by Wedbush from $186.00 to $187.00 in a research report report published on Friday, The Fly reports. A number of other research firms have also weighed in on ASND. StockNews.com started coverage on Ascendis Pharma A/S in a research note on Thursday, May […]
Finepoint Capital LP raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) by 8.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 134,036 shares of the biotechnology company’s stock after buying an additional 10,636 shares during the period. Ascendis Pharma A/S comprises […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) was the target of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 4,430,000 shares, a growth of 13.6% from the April 30th total of 3,900,000 shares. Based on an average trading volume of 806,600 shares, the […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) has received an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among […]